Cancer fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the ...

For roughly 400 years, microscopes have allowed us to observe increasingly smaller details. Today's most advanced instruments ...

“ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,” said Zachary Roberts, M.D ...

Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma. May 26, 2025 Chromophobe renal cell carcinoma (ChRCC) is the third most common type of RCC. There are no proven ...

The lead singer of 3 Doors Down, Brad Arnold, is adamant it's not his time yet. The 46-year-old vocalist shared on the band's social media on Wednesday that he had "some not-so-good news for you today ...

This study is indicating we need to think differently. These chromophobe kidney cancers, unfortunately, have very few immune cells; that's different from clear cell kidney cancer. Among those immune ...

1. Introduction Collecting duct carcinoma (CDC) of the kidney, known also as Bellini tumor, is a rare histological type of renal cell carcinoma (RCC) with distinctive clinical and histopathological ...

Among treatment-naive patients with metastatic renal cell carcinoma (RCC), exceptional response to immunotherapy were noted in patients with higher clonal neoantigen load, strong enrichment of B-cell ...

TOPLINE: Adjuvant everolimus does not improve recurrence-free or overall survival in patients with papillary and chromophobe subtypes of non–clear cell renal cell carcinoma (RCC) and is ...